The U.S. Patent and Trademark Office has already issued Complete Genomics two separate patents on LFR technology, and additional patent applications, including miniaturization using nanodrops, are pending. Complete Genomics plans to incorporate the new technology into its sequencing offerings in early 2013.
rumor, molec has gone past Comp.Gen. CEO Flatly wanted Comp.Gen, when rebuffed, worked around that and purchased two dr. quake entities, verinata health and moleculo. the forecast is, CEO Flatly will take moleculo far past anything Comp.Gen has and faster, using of course, its own platform. If you chart CEO Flatly's moves, he seems to sail straight into legal confrontations without regard. perhaps he has a skill at "courtside" negotiations once he put up a fierce legal off.-def. its too early to tell. but you cannot say he does not have vision for an end result, he just can't see any rocks directly in front of him. he is a wonderful legal client---RR